NCT03791814View on ClinicalTrials.gov

A Prospective Cohort Study to Improve HCV Care in Dialysis Patients

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 1, 2019

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Hepatitis C
Interventions
DRUG

Zepatier

Patients screened as HCV positive will receive Zepatier for 12 weeks.

Sponsors

Collaborators (1)

Davita Clinical Research
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Davita Clinical Research

INDUSTRY

lead

Albert Einstein Healthcare Network

OTHER

NCT03791814 - A Prospective Cohort Study to Improve HCV Care in Dialysis Patients | Biotech Hunter | Biotech Hunter